Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/13/2025

Choriocarcinoma Prognosis

General Prognosis

  • The American College of Obstetricians and Gynecologists notes that gestational choriocarcinoma has an excellent prognosis with cure rates exceeding 90-96% when appropriate chemotherapy is administered, even in high-risk disease 1, 2
  • The National Comprehensive Cancer Network recommends that overall survival depends critically on risk stratification using the FIGO scoring system, which incorporates age, previous pregnancy, interval since index pregnancy, pre-treatment hCG level, tumor size, sites of metastasis, number of metastases, and previous failed chemotherapy 1, 3

Prognostic Stratification by Risk Groups

  • The American Society of Clinical Oncology states that the cure rate reaches 100% with overall survival of 100% when appropriate single-agent chemotherapy is used in low-risk disease (FIGO score 0-6) 1
  • The National Comprehensive Cancer Network notes that methotrexate intramuscularly with folinic acid (MTX/FA) achieves complete primary response in 70-94% of cases 1
  • The European Society for Medical Oncology recommends that actinomycin-D achieves complete response in approximately 75% of patients resistant to methotrexate 1, 2

High-Risk Disease

  • The National Comprehensive Cancer Network recommends that cure rates approach 90% with the EMA/CO regimen as first-line treatment in high-risk disease (FIGO score ≥7 or stage IV) 2, 3
  • The American College of Obstetricians and Gynecologists notes that 5-year survival in high-risk disease is over 96% 1
  • The National Comprehensive Cancer Network states that approximately 30-40% of high-risk patients will have incomplete response to first-line therapy or experience relapse from remission 2
  • The European Society for Medical Oncology recommends that rescue therapy with regimens containing etoposide and platinum, frequently combined with surgical resection, results in cure of approximately 80-90% of patients with high-risk disease 2

Ultra-High-Risk Disease

  • The American Society of Clinical Oncology notes that ultra-high-risk disease (FIGO score ≥13) requires 1-3 cycles of low-dose etoposide-cisplatin (EP) before initiating EMA/CO to mitigate severe bleeding and metabolic disturbances 1
  • The European Society for Medical Oncology states that 5-year survival is 41-48% in patients with poor prognosis according to IGCCCG classification 4

Specific Prognostic Factors

  • The National Comprehensive Cancer Network recommends that brain metastases are associated with cure rates varying from 50-80%, depending on patient symptoms and number, size, and location of cerebral lesions 2, 3
  • The American College of Obstetricians and Gynecologists notes that approximately 20% of patients with choriocarcinoma present with brain metastases, requiring additional treatment considerations 3
  • The European Society for Medical Oncology states that the presence of metastatic choriocarcinoma indicates poor prognosis regardless of treatment modality 4

Fertility Prognosis

  • The American Society of Clinical Oncology notes that fertility is not affected after treatment for low-risk choriocarcinoma 6
  • The National Comprehensive Cancer Network recommends that fertility generally remains unchanged after EMA/CO, although advanced age at the start of treatment is an important factor 6
  • The European Society for Medical Oncology states that the risk of a second molar pregnancy is approximately 1% for complete mole and much lower for partial mole 6

Emerging Therapies for Resistant Disease

  • The National Comprehensive Cancer Network notes that the response to pembrolizumab treatment is durable in 3 out of 4 patients with drug-resistant disease 2, 5